Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)
Close on Nov 17, 2026Market cap $15.86BP/E –Yield –
Charles River Laboratories International ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Charles River Laboratories International's ebitda for the twelve months ending Jun 27, 2026 was $388.03M, down 30.0% year over year. For fiscal 2025 it was $428.47M, down 27.3% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $954.85M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $428.47M | -27.3% |
| FY2024 | Dec 28, 2024 | $589.09M | -36.8% |
| FY2023 | Dec 30, 2023 | $931.39M | -2.5% |
| FY2022 | Dec 31, 2022 | $954.85M | +11.6% |
| FY2021 | Dec 25, 2021 | $855.40M | +28.1% |
| FY2020 | Dec 26, 2020 | $667.65M | +21.6% |
| FY2019 | Dec 28, 2019 | $549.25M | +11.4% |
| FY2018 | Dec 29, 2018 | $493.16M | +17.6% |
| FY2017 | Dec 30, 2017 | $419.44M | +15.2% |
| FY2016 | Dec 31, 2016 | $364.21M | +20.9% |
| FY2015 | Dec 26, 2015 | $301.33M | +9.9% |
| FY2014 | Dec 27, 2014 | $274.12M | +10.5% |
| FY2013 | Dec 28, 2013 | $248.04M | +0.4% |
| FY2012 | Dec 29, 2012 | $247.04M | -4.8% |
| FY2011 | Dec 31, 2011 | $259.54M | – |
| FY2010 | Dec 25, 2010 | -$204.86M | -178.9% |
| FY2009 | Dec 26, 2009 | $259.58M | – |
| FY2008 | Dec 27, 2008 | -$364.99M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $187.18M | -14.8% |
| Q1 FY2026 | Mar 28, 2026 | $187.05M | -4.1% |
| Q4 FY2025 | Dec 27, 2025 | -$205.16M | – |
| Q3 FY2025 | Sep 27, 2025 | $218.96M | +6.5% |
| Q2 FY2025 | Jun 28, 2025 | $219.64M | -7.6% |
| Q1 FY2025 | Mar 29, 2025 | $195.03M | -7.7% |
| Q4 FY2024 | Dec 28, 2024 | -$65.58M | -130.7% |
| Q3 FY2024 | Sep 28, 2024 | $205.60M | -10.8% |
| Q2 FY2024 | Jun 29, 2024 | $237.73M | -2.0% |
| Q1 FY2024 | Mar 30, 2024 | $211.33M | -13.7% |
| Q4 FY2023 | Dec 30, 2023 | $213.44M | -11.6% |
| Q3 FY2023 | Sep 30, 2023 | $230.37M | +2.1% |
| Q2 FY2023 | Jul 1, 2023 | $242.62M | -8.0% |
| Q1 FY2023 | Apr 1, 2023 | $244.96M | +9.3% |
| Q4 FY2022 | Dec 31, 2022 | $241.36M | +0.5% |
| Q3 FY2022 | Sep 24, 2022 | $225.58M | +0.5% |
| Q2 FY2022 | Jun 25, 2022 | $263.83M | +28.3% |
| Q1 FY2022 | Mar 26, 2022 | $224.08M | +21.0% |
| Q4 FY2021 | Dec 25, 2021 | $240.05M | +26.5% |
| Q3 FY2021 | Sep 25, 2021 | $224.49M | +16.7% |
| Q2 FY2021 | Jun 26, 2021 | $205.66M | +53.5% |
| Q1 FY2021 | Mar 27, 2021 | $185.21M | +22.2% |
| Q4 FY2020 | Dec 26, 2020 | $189.80M | +18.2% |
| Q3 FY2020 | Sep 26, 2020 | $192.33M | +33.0% |
| Q2 FY2020 | Jun 27, 2020 | $133.98M | +3.9% |
| Q1 FY2020 | Mar 28, 2020 | $151.54M | +31.6% |
| Q4 FY2019 | Dec 28, 2019 | $160.62M | +11.5% |
| Q3 FY2019 | Sep 28, 2019 | $144.56M | +13.0% |
| Q2 FY2019 | Jun 29, 2019 | $128.91M | +7.3% |
| Q1 FY2019 | Mar 30, 2019 | $115.15M | +14.0% |
| Q4 FY2018 | Dec 29, 2018 | $144.06M | +49.6% |
| Q3 FY2018 | Sep 29, 2018 | $127.95M | +19.0% |
| Q2 FY2018 | Jun 30, 2018 | $120.11M | +5.8% |
| Q1 FY2018 | Mar 31, 2018 | $101.04M | -1.1% |
| Q4 FY2017 | Dec 30, 2017 | $96.31M | -8.0% |
| Q3 FY2017 | Sep 30, 2017 | $107.53M | +15.7% |
| Q2 FY2017 | Jul 1, 2017 | $113.49M | – |
| Q1 FY2017 | Apr 1, 2017 | $102.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $104.63M | – |
| Q3 FY2016 | Sep 24, 2016 | $92.90M | – |
See a number that looks wrong?